Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glaucoma and Ocular Hypertension Clear all
Completed Phase 4 Interventional Results available

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

NCT01525173
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops, latanoprost 0.005% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Deerfield Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 13, 2026, 7:49 PM EDT
Recruiting Not applicable Interventional

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

NCT05924477
View directory record Official record
Conditions
Glaucoma
Interventions
Sulcus tube placement, Anterior chamber (AC) tube placement
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
San Francisco, California • Walnut Creek, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Three Different Formulations of Prednisolone Acetate 1%

NCT00345046
View directory record Official record
Conditions
Glaucoma, Cataract
Interventions
Pred Forte, EconoPred Plus, Prednisolone Acetate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 13, 2026, 7:49 PM EDT
Not listed Not applicable Interventional

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

NCT05280366
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Streamline Surgical System, iStent Inject W
Device
Lead sponsor
New World Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
18
States / cities
Fayetteville, Arkansas • Newport Beach, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 13, 2026, 7:49 PM EDT
Not listed Not applicable Interventional

Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes

NCT02921568
View directory record Official record
Conditions
Retinal Disease, Glaucoma
Interventions
P200TE, Spectral OCT/SLO
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT01291108
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-210669, bimatoprost, bimatoprost vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 2 Interventional Results available

Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

NCT06144918
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo
Drug
Lead sponsor
Skye Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Glendale, California • Newport Beach, California • Cranberry Township, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 1 Interventional

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

NCT00638742
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Artesia, California • Atlanta, Georgia • North Dartmouth, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04742283
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Normative Database for Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG)

NCT02609204
View directory record Official record
Conditions
Glaucoma
Interventions
Diopsys NOVA
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 2 Interventional Results available

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

NCT02874846
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

NCT00441883
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
Interventions
PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Not applicable Interventional

Effect of Intra-subject Phaco/Trabectome vs. Phaco/Kahook Dual Blade on Intraocular Pressure

NCT03894631
View directory record Official record
Conditions
Glaucoma
Interventions
KDB/Phacoemulsification, Trabectome/Phacoemulsification
Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 95 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 1Phase 2 Interventional

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT01410188
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Ocular Hypertension
Interventions
OPA-6566, Placebo, Latanoprost
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Artesia, California • Glendale, California • Roswell, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 13, 2026, 7:49 PM EDT
Active, not recruiting Phase 2 Interventional

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions
QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Not applicable Interventional Results available

Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma

NCT01105065
View directory record Official record
Conditions
Glaucoma
Interventions
brimonidine 0.15%
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
35 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 13, 2026, 7:49 PM EDT
Completed No phase listed Observational Results available

A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System

NCT05044793
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Wichita, Kansas • Oklahoma City, Oklahoma • Jenkintown, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

NCT00451152
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 13, 2026, 7:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

NCT07770685
View directory record Official record
Conditions
Glaucoma
Interventions
ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 13, 2026, 7:49 PM EDT
Terminated Not applicable Interventional Results available

Reliability and Reproducibility of the Eye Check Tonometer

NCT04639947
View directory record Official record
Conditions
Glaucoma, Glaucoma, Suspect
Interventions
EyeCheck, Traditional Tonometer (Goldmann and Tonopen)
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

NCT02855450
View directory record Official record
Conditions
Glaucoma
Interventions
rhNGF, Vehicle
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 13, 2026, 7:49 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy

NCT01345448
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine, Placebo Lotion
Drug
Lead sponsor
Nanduri, Padma, M.D., FACS
Individual
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Visalia, California
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 13, 2026, 7:49 PM EDT
Completed Phase 2 Interventional

Ocular Hypotensive Efficacy of AR-102

NCT00523250
View directory record Official record
Conditions
Glaucoma
Interventions
AR-102 0.003% Ophthalmic Solution, AR-102 0.005% Ophthalmic Solution, AR-102 0.01% Ophthalmic Solution, AR-102 0.03% Ophthalmic Solution, AR-102 Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 13, 2026, 7:49 PM EDT
Terminated Not applicable Interventional Results available

Anterior-segment OCT (AS-OCT) and Intraoperative OCT (iOCT) for Trans- Conjunctival Needle Revision (TCNR)

NCT05790408
View directory record Official record
Conditions
Glaucoma, Glaucoma Following Surgery
Interventions
Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 13, 2026, 7:49 PM EDT